{"id":"W4411229260","doi":"10.1016/j.esmoop.2025.105303","title":"Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374)","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada); Princess Margaret Cancer Centre","funders":"Genentech; Sun Pharma; Natera; Relay Therapeutics; Seagen; MacroGenics; Puma Biotechnology; Loxo Oncology; Ribon Therapeutics; BeiGene; Mersana Therapeutics; Les Laboratories Pierre Fabre; Astellas Pharma; Eisai; Jazz Pharmaceuticals; F. Hoffmann-La Roche; AstraZeneca; Invitae; Daiichi Sankyo Europe; National Cancer Institute; Servier; Gilead Sciences; Sanofi; Memorial Sloan-Kettering Cancer Center; GlaxoSmithKline; Amgen; Pfizer; Celgene; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Breast cancer; Medicine; Oncology; HER2 negative; Internal medicine; Cancer; Metastatic breast cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002530112,0.0001916452,0.0005208497,0.0001876764,0.00004684271,0.00002281334,0.0001368158,0.00005745336,0.00006453307],"category_scores_gemma":[0.000009823146,0.0001760583,0.00002143021,0.0005623894,0.0001680872,0.0003724219,0.0002512301,0.0001565279,6.205772e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002506741,"about_ca_system_score_gemma":0.00006539113,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005068208,"about_ca_topic_score_gemma":0.003803594,"domain_scores_codex":[0.9988431,0.00009682016,0.0003509705,0.0003558354,0.0001514587,0.0002018021],"domain_scores_gemma":[0.999451,0.00008930904,0.0001233075,0.0001987467,0.00009453245,0.00004304975],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.01060132,0.0007621449,0.1869582,0.001466775,0.0006078653,0.00009410978,0.005176598,0.0002179092,0.000550268,0.008537436,0.00003531629,0.7849921],"study_design_scores_gemma":[0.01346793,0.000100116,0.9746002,0.004204675,0.00005070556,0.00001422174,0.001766279,0.0001101221,0.001196074,0.003681557,0.000653524,0.0001545755],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9788796,0.007993111,0.0001841867,0.006883678,0.00008779468,0.002618002,0.00008361274,0.00002097052,0.003249069],"genre_scores_gemma":[0.9839956,0.01275637,0.001946211,0.0005736463,0.000006638006,0.0002325397,0.00002001027,0.00001936373,0.0004496069],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7876421,"threshold_uncertainty_score":0.7661648,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01318522498311948,"score_gpt":0.3310736711880635,"score_spread":0.3178884462049441,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}